Dyspnea News and Research

RSS

Dyspnea or dyspnoea or shortness of breath is a debilitating symptom that is the experience of unpleasant or uncomfortable respiratory sensations.

GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

GE Healthcare today announced the first seven markets where Vizamyl (Flutemetamol F18 injection), a radioactive diagnostic agent approved by the FDA will be available. Late in the second quarter of 2014, Vizamyl will be available to imaging centers near East Rutherford, NJ, Woburn, MA, Beltsville, MD, East Lansing, MI, Dallas, TX, Phoenix, AZ and Colton, CA.

29 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

Stem cell research institute of STC Life Co., Ltd. (Chairman: KYE HO LEE) and 97.7 B&H Clinic (Representative Doctor: WON JU JUNG) successfully finished mesenchymal stem cell therapy for the pulmonary fibrosis patient who visited Korea from Calgary, Canada.

12 Mar 2014

Dyspnea during light daily activities used as indicator of exercise intolerance and low fitness

Dyspnea, a sensation of breathlessness, during light daily activities can be used as an indicator of exercise intolerance and low fitness. According to a study on Finnish twins, persistent or developing dyspnea reveals an increased risk of death.

21 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G-protein coupled receptor biased ligands, announced today initiation of dosing in BLAST-AHF, the Company's randomized, multi-center Phase 2b trial of TRV027 in patients with acute heart failure.

9 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Cycle test reliable for dyspnea evaluation in obese COPD patients

Dyspnea in obese individuals with chronic obstructive pulmonary disease can be evaluated reliably by cycle ergometry as well as a treadmill test, researchers have found.

20 Dec 2013

Cetuximab fails in second-line combination for recurrent NSCLC

Results from a phase III trial indicate that cetuximab should not be given alongside chemotherapy in patients with recurrent non-small-cell lung cancer after platinum-based therapy.

13 Dec 2013

Detectable blood viral load increases prevalence of heart disease

HIV causes structural heart disease according to research presented at EuroEcho-Imaging 2013 by Dr Nieves Montoro from Madrid, Spain. The findings support the introduction of cardiovascular screening in all HIV patients, particularly those with a positive blood viral load.

11 Dec 2013

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that results from two studies of REVLIMID (lenalidomide) combinations in patients with diffuse large B-cell lymphoma (DLBCL) were presented at the American Society of Hematology annual meeting in New Orleans, La.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. today announced that the company is acquiring exclusive rights in the United States for Saphris (asenapine) sublingual tablets, a treatment for adult patients with schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc.

3 Dec 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

QoL, BMI predict exacerbations in Japanese COPD patients

Analysis of a cohort of Japanese chronic obstructive pulmonary disease patients with a low exacerbation frequency shows that low body mass index and poor health-related quality of life independently predict flare ups of the disease.

21 Nov 2013

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

The U.S. Food and Drug Administration today approved Imbruvica (ibrutinib) to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

13 Nov 2013

Community pharmacist program improves COPD care

Patients with chronic obstructive pulmonary disease who receive a community pharmacist-based intervention have improved inhalation technique and medication adherence, show the results of a randomized trial.

5 Nov 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Clinical attention improves QoL in COPD

A study in the primary care setting shows that clinical factors have the greatest influence on improving health-related quality of life in patients with chronic obstructive pulmonary disease.

17 Oct 2013

Dyspnea News and Research

Further Reading

GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

STC Life and 97.7 B&H Clinic successfully treat pulmonary fibrosis patient

Dyspnea during light daily activities used as indicator of exercise intolerance and low fitness

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Trevena doses first patient in TRV027 Phase 2b trial for acute heart failure

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Cycle test reliable for dyspnea evaluation in obese COPD patients

Cetuximab fails in second-line combination for recurrent NSCLC

Detectable blood viral load increases prevalence of heart disease

Celgene subsidiary presents REVLIMID study results on lymphoma at ASH annual meeting

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Forest Laboratories to acquire exclusive rights in the U.S. for Saphris sublingual tablets

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

QoL, BMI predict exacerbations in Japanese COPD patients

Imbruvica gets FDA approval for treatment of mantle cell lymphoma

Community pharmacist program improves COPD care

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Clinical attention improves QoL in COPD

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News